1. Almyroudis N, Jaffe D, Sepkowitz KA, Pamer EG, Meier EN, Papadopoulos E, Small TN, Papanicolaou GA (2003) Risk factors for late invasive aspergillosis (IA) after allogeneic stem cell transplantation. In: 43rd ICAAC abstracts, American Society for Microbiology, September 2003, p 457, M-1006
2. Ascioglu S, Rex JH, de Pauw B et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7?14
3. Bischoff TR, Tallent S, Adera T, Wenzel RP, Edmond MB (2003) Epidemiology of nosocomial candidemia: a six-year national perspective. In: 43rd ICAAC abstracts, American Society for Microbiology, September 2003, p 348, K 452e
4. Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, Novitzky N, Boehme A, Chwetzoff E, De Beule K (2001) Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 135:412?422
5. Bow EJ, Laverdière M, Lussier N, Rotstein C, Cheang MS, Ioannou S (2002) Antifungal prophylaxis for severely neutropenic chemotherapy recipients. A meta-analysis of randomized-controlled clinical trials. Cancer 94:3230?3246